Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2020-04-24 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
2019年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2019 Annual Report Summary" of 江苏四环生物股份有限公司, indicating it is a summary of the full annual report. It contains detailed financial data for the year 2019, including revenue, net profit, quarterly financial data, business overview, industry analysis, shareholder information, and accounting policy changes. The document is over 7,000 characters, which is substantial and contains actual financial statements and analysis, not just an announcement or a brief summary. It is clearly a financial report covering the full fiscal year 2019. Therefore, it fits the definition of an Annual Report (10-K). FY 2019
2020-04-24 Chinese
独立董事关于续聘会计师事务所的事前认可
Audit Report / Information Classification · 90% confidence The document is a short statement from independent directors regarding the pre-approval of the reappointment of an accounting firm for audit services. It references regulatory rules and confirms the qualifications of the accounting firm. The document is only 414 characters long and does not contain any financial data or detailed audit results. It is not a full audit report but rather an approval or endorsement related to audit services. Therefore, it fits best under Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or financial statement. FY 2019
2020-04-24 Chinese
关于公司非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告
Regulatory Filings
2020-04-24 Chinese
关于召开2019年年度股东大会通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2019 Annual General Meeting (AGM) of Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. It includes details about the meeting date, voting procedures, agenda items to be discussed (such as the 2019 annual report, financial statements, profit distribution plan, and appointment of auditors), and instructions for shareholders on how to attend and vote. The document does not contain the actual annual report or financial statements but rather serves as an announcement and invitation to the AGM. The document length is 3783 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2020-04-24 Chinese
第八届董事会第十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the company's board meeting, detailing the approval of the 2019 annual report, financial statements, profit distribution plan, remuneration, internal control report, and other related matters. It includes voting results and mentions that these items will be submitted to the shareholders' meeting for approval. The document is not the full annual report itself but a board meeting resolution announcement regarding the annual report and related items. The document length is short (1513 characters) and primarily contains meeting resolutions and voting results, not the full financial report or detailed financial data. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2020-04-24 Chinese
2019年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' which translates to 'Audit Report'. It contains detailed audit opinions, key audit matters, and extensive financial statement notes. The content includes auditor's responsibilities, management's responsibilities, and detailed audit procedures, which are typical components of a standalone audit report. The document is about the audit of the financial statements for the year ended December 31, 2019, and it is issued by a certified public accounting firm. It is not an annual report or a regulatory filing announcement but a full audit report. Therefore, the appropriate classification is 'AR' for Audit Report / Information.
2020-04-24 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.